Ambassador Susan C. Schwab

Ambassador Schwab served as U.S. Trade Representative (2006–09) and as deputy (2005–06).

As USTR, she concluded free trade agreements with Peru, Colombia, South Korea and others; and launched the Trans-Pacific Partnership (TPP) negotiations.  She pursued and/or settled trade disputes with various WTO members, including China, Canada, and the EU, and engaged in negotiations at the WTO, APEC and other multilateral institutions.

In academia, she served as dean of the School of Public Policy at the University of Maryland; and as vice chancellor of the University System of Maryland (USM) & CEO of the USM Foundation.  She still teaches classes in international trade.

In the private sector, Schwab was director of corporate business development for Motorola, Inc., where she engaged in M&A and joint venture negotiations in Asia, including in China.

Earlier in government, she served as assistant secretary of Commerce and director-general of the U.S. & Foreign Commercial Service, as a trade staffer and legislative director for Senator John C. Danforth (R-MO), and as a foreign service officer at the US Embassy in Tokyo.  She began her career as an agricultural trade negotiator at USTR.

Ambassador Schwab serves on the boards of Caterpillar, FedEx and Marriott, as well as The Conference Board, Business Council for International Understanding (BCIU), Lee Kuan Yew School of Public Policy, and Signature Theatre of Arlington, VA.  She chairs the board of The National Foreign Trade Council (NFTC).

She holds a BA from Williams College; a Master’s from Stanford University; and a Ph.D. from The George Washington University.

Andrei Iancu – Congressional Testimony: Hearing on the Patent Eligibility Restoration Act (PERA)

On October 8th, 2025, Andrei Iancu testified before the Senate Judiciary Committee, Subcommittee on Intellectual Property during the Hearing on the Patent Eligibility Restoration Act (PERA). Iancu, Partner at Sullivan & Cromwell, former Under Secretary of Commerce for IP and Director of the U.S. Patent and Trademark Office (USPTO), and
Read More

How Europe Lost Global Biopharmaceutical R&D Leadership to the United States: Lessons for Today

By Anne Prichett Today, the United States leads the world in biopharmaceutical industry research and development (R&D), supporting nearly five million jobs and generating more than $1.65 trillion in economic output. This position of global leadership, however, is relatively recent. Until the late 1980s, Europe–particularly Germany, France,
Read More

If Private Sector R&D Is the Future, IP Policy Must Catch Up

By Chris Borges The President’s Budget Request for fiscal year 2026 (FY 2026) includes steep cuts to federal research and development (R&D) funding—a troubling signal for U.S. innovation and economic security. While congressional committees may push back on the most severe reductions, the signs are clear: Federal R&D funding is likely
Read More